PEG-rhG-CSF对80例小细胞肺癌同步放化疗预防中性粒细胞减少的临床观察

doi:10.6040/j.issn.1671-7554.0.2020.0925

摘要/Abstract

摘要： 目的探讨聚乙二醇化重组人粒细胞集落刺激因子(PEG-rhG-CSF)在小细胞肺癌患者同步放化疗中中性粒细胞减少的预防效果。方法回顾性分析在山东省肿瘤医院行同步放化疗、且预防使用PEG-rhG-CSF的小细胞肺癌病例80例(观察组),根据年龄、性别等因素1∶1匹配了未使用PEG-rhG-CSF的对照组80例。观察比较两组的中性粒细胞减少情况。结果同步放化疗后,观察组和对照组的白细胞均减少,但前者(3.15±0.76)×10⁹个/L高于后者(1.82±0.77)×10⁹个/L,差异有统计学意义(Z=-8.467,P<0.001);观察组与对照组同步放化疗前,两组中性粒细胞绝对值差异无统计学意义(Z=-1.543,P=0.123),同步放化疗后观察组中性粒细胞减至(1.89±0.52)×10⁹个/L,对照组减至(0.77±0.44)×10⁹个/L,观察组绝对值减少幅度低于对照组,差异有统计学意义(Z=-10.034,P<0.001)。结论使用PEG-rhG-CSF对预防白细胞、中性粒细胞绝对值的降低有作用,可改善中性粒细胞减少,但尚待大样本验证。

关键词: 聚乙二醇化重组人粒细胞集落刺激因子, 小细胞肺癌, 同步放化疗, 骨髓抑制, 预防效果

Abstract: Objective To investigate the preventive effect of pegylated recombinant human granulocyte colony stimulating factor(PEG-rhG-CSF)on neutropenia in patients with small cell lung cancer(SCLC). Methods A retrospective analysis of 80 SCLC cases(observation group)who received concurrent chemoradiotherapy and prophylactic use of PEG- rhG-CSF in Shandong Cancer Hospital was conducted, and 80 controls without useing PEG-rhG-CSF were matched according to age, gender and other factors. The neutropenia was observed and compared between the two groups. Results After concurrent chemoradiotherapy, the leukocytes count decreased in both groups, which was(3.15±0.76)×10⁹ cells/L in the observation group and(1.82±0.77)×10⁹ cells/L in the control group (Z=-8.467, P<0.001). Before chemoradiotherapy, there was no significant difference in the absolute value of neutrophils between the two groups(Z=-1.543, P=0.123). After chemoradiotherapy, the number of neutrophils decreased to(1.89±0.52)×10⁹ cells/L in the observation group and(0.77±0.44)×10⁹ cells/L in the control group. The decrease in the observation group was lower than that in the control group (Z=-10.034, P<0.001). Conclusion PEG-rhG-CSF can prevent the decrease of leukocytes and neutrophils, but experiments with larger samples are still needed for proof.

Key words: Pegylated recombinant human granulocyte colony stimulating factor, Small cell lung cancer, Concurrent radiotherapy and chemotherapy, Myelosuppression, Preventive effect

中图分类号:

R734.2

张喜琴,祝守慧,刘宁,王玉,陈家帧,胡旭东. PEG-rhG-CSF对80例小细胞肺癌同步放化疗预防中性粒细胞减少的临床观察[J]. 山东大学学报 (医学版), 2020, 58(12): 43-46.

ZHANG Xiqin, ZHU Shouhui, LIU Ning, WANG Yu, CHEN Jiazhen, HU Xudong. Clinical observation of PEG-rhG-CSF in preventing neutropenia in 80 patients with small cell lung cancer treated with concurrent chemoradiotherapy[J]. Journal of Shandong University (Health Sciences), 2020, 58(12): 43-46.

参考文献

[1] Cheng TY, Cramb SM, Baade PD, et al. The International Epidemiology of Lung Cancer: Latest Trends, Disparities, and Tumor Characteristics [J]. J Thorac Oncol, 2016, 11(10): 1653-1671.
[2] 吴军, 杨小平. 分子靶向药物治疗非小细胞肺癌的研究进展[J]. 医学理论与实践, 2019, 32(10): 1489-1490. WU Jun, YANG Xiaoping. Advances in molecular targeting therapy for non-small cell lung cancer [J]. Medical Theory and Practice, 2019, 32(10): 1489-1490.
[3] 杨晨, 何小慧, 刘鹏, 等. 聚乙二醇化重组人粒细胞集落剌激因子预防化疗后中性粒细胞减少的有效性分析[J]. 中国肿瘤临床, 2015, 12(1): 626. YANG Chen, HE Xiaohui, LIU Peng, et al. Analysis of the efficacy of pegylated recombinant human granulocyte colony stimulating factor in the prevention of neutropenia after chemotherapy [J]. Chinese Oncology Clinic, 2015, 12(1): 626.
[4] 张冀伟. 聚乙二醇化重组人粒细胞集落刺激因子在预防小细胞肺癌化疗后中性粒细胞减少症的有效性分析[D]. 天津: 天津医科大学, 2018: 1-45.
[5] 许素真, 陈淑如. 重组人粒细胞集落刺激因子应用在乳腺癌化疗后骨髓抑制的预防效果分析[J]. 吉林医学, 2019, 40(3): 550-551. XU Suzhen, CHEN Shuru. Analysis of the preventive effect of recombinant human granulocyte colony stimulating factor on bone marrow suppression after breast cancer chemotherapy [J]. Jilin Medical Science, 2019, 40(3): 550-551.
[6] 莫红楠, 石远凯, 孙燕. 重组人粒细胞集落刺激因子在肿瘤化疗中应用 20 年回顾[J]. 中国新药杂志, 2013, 22(17): 2027. MO Hongnan, SHI Yuankai, SUN Yan. A 20-year review of the application of recombinant human granulocyte colony stimulating factor in tumor chemotherapy [J]. Chinese Journal of New Drugs, 2013, 22(17): 2027.
[7] 左金曼, 夏瑞祥. 重组人粒细胞集落刺激因子联合抗生素治疗急性白血病化疗后中性粒细胞缺乏合并感染患者的疗效[J]. 中国老年学杂志, 2016, 36(20): 5064-5066. ZUO Jinman, XIA Ruixiang. Efficacy of recombinant human granulocyte colony stimulating factor combined with antibiotics in the treatment of patients with neutropenia complicated with infection after chemotherapy in acute leukemia [J]. Chinese Journal of Gerontology, 2016, 36(20): 5064-5066.
[8] 陈琰, 陈坚, 张建华. 聚乙二醇化重组人粒细胞集落刺激因子在恶性肿瘤化疗后骨髓抑制患者中的应用[J].实用临床医药杂志,2019,23(23):61-63. CHEN Yan, CHEN Jian, ZHANG Jianhua. The application of pegylated recombinant human granulocyte colony-stimulating factor in patients with myelosuppression after chemotherapy of malignant tumor [J]. Journal of practical clinical medicine, 2019,23(23): 61-63.
[9] 范奎, 代良敏, 伍振峰, 等. 放化疗所致骨髓抑制的研究进展[J].中华中医药杂志,2017,32(1):210-214. FAN Kui, DAI Liangmin, WU Zhenfeng, et al. Progress in research on myelosuppression induced by chemoradiotherapy [J]. Chinese Journal of traditional Chinese medicine, 2017,32(1): 210-214.
[10] 宋君利, 陈明达, 艾建中, 等. PEG-rhG-CSF对以顺铂为基础联合化疗所致骨髓抑制的预防作用[J]. 实用癌症杂志,2017,32(10):1725-1727. SONG Junli, CHEN Mingda, AI Jianzhong,et al. The preventive effect of PEG- rhG- CSF on bone marrow suppression induced by cisplatin based chemotherapy [J]. Journal of practical cancer, 2017,32(10): 1725-1727.
[11] 贺晶晶, 高俊珍. 聚乙二醇化重组人粒细胞集落刺激因子的应用进展[J]. 国际呼吸杂志,2020,40(16):1255-1261. HE Jingjing, GAO Junzhen. Progress in the application of pegylated recombinant human granulocyte colony stimulating factor [J]. International Journal of respiration, 2020,40(16): 1255-1261.
[12] 李惠平, 樊征夫, 郑虹, 等. 聚乙二醇化重组人粒细胞集落刺激因子初级与次级预防化疗后中性粒细胞减少的有效性和安全性临床研究[J]. 中国肿瘤临床, 2019, 46(14): 739-744. LI Huiping, FAN Zhengfu, ZHENG Hong, et al. Clinical study on the efficacy and safety of pegylated recombinant human granulocyte colony stimulating factor in primary and Secondary prevention of neutropenia after chemotherapy [J]. Chinese Oncology Clinic, 2019, 46(14): 739-744.
[13] 张嘉扬, 刘雅昕, 王环, 等. 预防性应用长效粒细胞集落刺激因子在乳腺癌辅助化疗中的作用[J]. 中华医学杂志, 2018, 98(34): 2718-2721. ZHANG Jiayang, LIU Yaxin, WANG Huan, et al. Effect of prophylactic application of long-acting granulocyte colony stimulating factor in adjuvant chemotherapy for breast cancer [J]. Chinese Journal of Medicine, 2018, 98(34): 2718-2721.
[14] Shin KH, Lim KS, Lee H, et al. An assessment of the pharmacokinetics, pharmacodynamics, and tolerability of GCPGC, a novel pegylated granulocyte colony-stimulating factor(G-CSF), in healthy subjects [J]. Invest New Drugs, 2014, 32(4): 636‐643.
[15] 王海英, 刘莹, 胡盼, 李佳睿. 聚乙二醇化重组人粒细胞刺激因子预防老年恶性B细胞淋巴瘤化疗后中性粒细胞减少症的临床观察[J]. 中国老年学杂志, 2019, 39(24): 5961-5963. WANG Haiying, LIU Ying, HU Pan, et al. Clinical observation of pegylated recombinant human granulocyte stimulator in the prevention of neutropenia after chemotherapy for senile malignant B-cell lymphoma [J]. Chinese Journal of Gerontology, 2019, 39(24): 5961-5963.
[16] Pfeil AM, Allcott K, Pettengell R, et al. Efficacy, effectiveness and safety of long-acting granulocyte colony-stimulating factors for prophylaxis of chemotherapy-induced neutropenia in patients with cancer: a systematic review [J].Support Care Cancer, 2015, 23(2): 525‐545.
[17] 蔡智慧, 田肖芳, 李蕾, 等. 聚乙二醇化重组人粒细胞集落刺激因子联合生血宝合剂预防恶性肿瘤化疗后骨髓抑制的临床观察[J]. 广西医学, 2020, 42(1): 21-23. CAI Zhihui, TIAN Xiaofang, LI Lei, et al. Clinical observation of pegylated recombinant human granulocytic colony stimulating factor combined with Shengxuebao Mixture in the Prevention of bone marrow suppression after chemotherapy for malignant Tumors [J]. Guangxi Medical Science, 2020, 42(1): 21-23.
[18] Xie J, Cao J, Wang JF, et al. Advantages with prophylactic PEG-rhG-CSF versus rhG-CSF in breast cancer patients receiving multiple cycles of myelosuppressive chemotherapy: an open-label, randomized, multicenter phase Ⅲ study [J]. Breast Cancer Res Treat, 2018, 168(2): 389-399.

相关文章 15

[1]	黄佩文, 王旭东. 治疗非小细胞肺癌新药:靶向c-Met蛋白的抗体药物偶联物Telisotuzumab Vedotin[J]. 山东大学学报 (医学版), 2026, 64(3): 124-130.
[2]	赵汉卿,周新睿,李子建,唐兴. 循环肿瘤细胞联合血清学检测在非小细胞肺癌中的应用[J]. 山东大学学报 (医学版), 2025, 63(5): 79-85.
[3]	徐年兴,魏东,乔俊杰,战炳炎. CD8⁺、IL-6和PaO₂对不可切除Ⅲ_B/C和Ⅳ期非小细胞肺癌免疫治疗触发放射召回性肺炎的预测价值[J]. 山东大学学报 (医学版), 2025, 63(2): 29-35.
[4]	山东省腔镜外科质量控制中心胸腔镜委员会. 山东省VATS/RATS非小细胞肺癌围术期质量控制指标专家共识(2025版)[J]. 山东大学学报 (医学版), 2025, 63(12): 1-5.
[5]	刘振昆,吕纪玲,徐伟伟,马力天,张才擎. BALF tNGS检测及培养对NSCLC合并IPFD的诊断价值[J]. 山东大学学报 (医学版), 2025, 63(11): 36-45.
[6]	张荣雨,赵文,李洪欣,杨闯,王健,韩春燕,李际盛. 奥西替尼联合化疗一线治疗EGFR-RAD51融合突变转移性肺腺癌1例[J]. 山东大学学报 (医学版), 2024, 62(5): 116-120.
[7]	王蕾,向淇,刘学伍. 伴系统性硬化症、类风湿关节炎的副肿瘤神经综合征1例[J]. 山东大学学报 (医学版), 2023, 61(7): 118-120.
[8]	秦静,杨飞,陈谦,夏涵岱,刘延国,王秀问. 晚期驱动基因阴性、PD-L1表达阴性非鳞非小细胞肺癌一线治疗方案的网状Meta分析[J]. 山东大学学报 (医学版), 2022, 60(7): 74-82.
[9]	陈兆波,方敏,薛浩然,刘春艳. 去泛素化酶USP35促进非小细胞肺癌细胞迁移和侵袭[J]. 山东大学学报 (医学版), 2022, 60(4): 30-37.
[10]	马瑞杰,朱良明,左太阳,李春海,张楠,孙志钢. 微波消融治疗非小细胞肺癌根治术后肺寡转移瘤的预后分析[J]. 山东大学学报 (医学版), 2022, 60(12): 63-68.
[11]	刘会宁,彭军,任迎春,杨光,王文豪,刘金锋,田勍. 34例胸腔镜下肺楔形切除与21例肺段切除对位于肺段P区的ⅠA1期非小细胞肺癌治疗比较[J]. 山东大学学报 (医学版), 2022, 60(11): 38-43.
[12]	丁子琛,王浩桦,周立雯,丛慧文,李承圣,包绮晗,杨毅,王廉源,王素珍,石福艳. 基于贝叶斯累加回归树模型的非小细胞肺癌患者个性化疗效研究[J]. 山东大学学报 (医学版), 2022, 60(10): 92-98.
[13]	刘小璟,夏西燕,肖珂,陈文丹,庄学伟. 外泌体lncRNA OGFRP1在84例非小细胞肺癌中的表达及临床意义[J]. 山东大学学报 (医学版), 2020, 58(11): 71-75.
[14]	魏萍,杜鲁涛,王卿,展垚,谢玉姣,张淑君,段伟丽,王传新. 血清外泌体miR-20b-5p对非小细胞肺癌的诊断价值[J]. 山东大学学报 (医学版), 2019, 57(4): 91-96.
[15]	王伟,刘拥征,李岭. 酸浆苦素B对人非小细胞肺癌细胞增殖、迁移及凋亡的影响[J]. 山东大学学报 (医学版), 2019, 57(3): 13-18.

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed